Corporate ProfileIgniting Future SurgeryEnlightening the Life The core team of WEISEBOT originates from the State Key Laboratory of Robotics and Systems at Harbin Institute of Technology.Since 2003,we have been dedicated to foundational R&D for surgical robots,making us one of the earliest pioneers in the field in China.We have undertaken key national R&D projects for minimally invasive surgical robots during the 11th,12th,and 13th Five-Year Plan periods,accumulating profound expertise in critical technologies such as mechanical architecture and core algorithms. Through our synergistic 'Industry-University-Research-Medicine-Inspection"model, we work closely with numerous hospitals and research institutions to accurately address clinical needs,which has earned us widespread recognition from industry experts.We have developed a comprehensive product portfolio that includes multi-port and single-port laparoscopic surgical robots,along with supporting instruments.Our four-arm multi-port laparoscopic surgical robot,the first of its kind approved for market in Zhejiang Province,has become a new hallmark of "Zhejiang- made'innovation in the high-end medical equipment sector. As a surgical robotics platform strategically invested in by Kangji Medical(09997. HK),we fully leverage the group's strategic resources and ndustrial synergies to integrate resources across the entire industry chain.Supported by the layout of Hangzhou headquarters and Tonglu mass production base,we are committed to accelerating the domestic substitution of advanced medical equipment. WEISEBOT is dedicated to serving clinical practice with precise,minimally invasive advanced technologies.We work in partnership with medical professionals to pursue excellence,bringing unparalleled precision to life. Pioneering researchin minimlly invasivesurgical robotics Deep and Specializedaccumulation in robottechnology Consistently leadingkey national R&Dinitiatives Mastering underlyingtechnologies to enabledomestic alternatives 2003-2017 Technology Breakthrough 2018-2023 Clinical Validation Formed core R&D team,commencing pioneering research on common key technologies for surgical robots. Undertook the "11th Five-Year·863 Program" for minimally invasive surgical robots. Served as lead institution in the "12th Five-Year·863 Program"for minimally invasive surgical robots. Undertook the "13th Five-Year" Natlonal R&D Project for minimally invasive surgical robots Core team initiated industrialization of minimally invasive surgical robots in Changzhou,Jiangsu. Established headquarters and production base in Hangzhou. Secured RMB 360 million strategic investment from Kangji Medical (09997HK). Relocated headquarters to Future Si-Tech City,Yuhang District,Hangzhou. Led and secured approval of the 2023 Zhejiang "JianBing" R&D Program. Completed enrollment of 120 cases in clinical trial the first laparoscopic surgical robot. Designated as an "Innovative SME". Recognized as a "Zhejiang Provincial Sci-Tech SME". Cerified as a National High-Tech Enterprise. Signed strategic agreement for the Tonglu National Mass Production Base. Received NMPA approval for laparoscopic surgical robot system,indicated for urology,general surgery and gynecology. Completed patient enrollment for thoracic surgery clinical trial. Igniting Future Surgery, Enlightening the Life. Committed to delivering reliable, accessible, and sustainable robotic surgical solutions, and be the leader of intelligent surgery. Integrity, Aspiration, Commitment, Innovation National Qualification for the First-Unit (Set) of Major Technical Equipment National High-Tech Enterprise (2024) National Science and Technology-Based SME (2023) Lead Innovator, AI Medical Device Innovation Task, MIIT (2025) Exemplary AI Application Scenario for SMEs, MIIT (2025) Zhejiang Specialized and Sophisticated SME (2025) Zhejiang Provincial Enterprise Research Institute (2025) Hangzhou Semi-Unicorn Enterprise (2025) Zhejiang Science and Technology-Based SME (2023) Hangzhou Exemplary Robotics Application Scenario (2025)